Mediclinic International plc

BATS-CHIXE:MDCL Stock Report

Market Cap: UK£3.7b

Mediclinic International Valuation

Is MDCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MDCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MDCL (£5) is trading above our estimate of fair value (£4.06)

Significantly Below Fair Value: MDCL is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDCL?

Key metric: As MDCL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MDCL. This is calculated by dividing MDCL's market cap by their current earnings.
What is MDCL's PE Ratio?
PE Ratio21.9x
EarningsUK£169.00m
Market CapUK£3.69b

Price to Earnings Ratio vs Peers

How does MDCL's PE Ratio compare to its peers?

The above table shows the PE ratio for MDCL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.4x
SPI Spire Healthcare Group
31.3x26.9%UK£884.7m
CVSG CVS Group
22.5x15.5%UK£589.7m
CTEC ConvaTec Group
40.1x20.4%UK£4.8b
SN. Smith & Nephew
35.7x22.5%UK£8.6b
MDCL Mediclinic International
21.9x10.7%UK£3.7b

Price-To-Earnings vs Peers: MDCL is good value based on its Price-To-Earnings Ratio (21.9x) compared to the peer average (61x).

Price to Earnings Ratio vs Industry

How does MDCL's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MDCL is expensive based on its Price-To-Earnings Ratio (21.9x) compared to the European Healthcare industry average (17.1x).

Price to Earnings Ratio vs Fair Ratio

What is MDCL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDCL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.9x
Fair PE Ratio44.8x

Price-To-Earnings vs Fair Ratio: MDCL is good value based on its Price-To-Earnings Ratio (21.9x) compared to the estimated Fair Price-To-Earnings Ratio (44.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MDCL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Nov ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Oct ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Sep ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Aug ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Jul ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Jun ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
May ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Apr ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Mar ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Feb ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Jan ’25n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Dec ’24n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Nov ’24n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Oct ’24n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Sep ’24n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Aug ’24n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Jul ’24n/a
UK£4.95
0%
3.2%UK£5.04UK£4.64n/a5
Jun ’24UK£5.00
UK£4.95
-1.0%
3.2%UK£5.04UK£4.64n/a5
May ’24UK£4.98
UK£4.95
-0.6%
3.2%UK£5.04UK£4.64n/a5
Apr ’24UK£4.98
UK£4.95
-0.4%
3.2%UK£5.04UK£4.64n/a5
Mar ’24UK£4.98
UK£4.95
-0.5%
3.2%UK£5.04UK£4.64n/a5
Feb ’24UK£4.97
UK£4.96
-0.2%
2.9%UK£5.04UK£4.64n/a6
Jan ’24UK£4.97
UK£4.92
-0.9%
3.3%UK£5.04UK£4.64n/a7
Dec ’23UK£4.97
UK£4.92
-0.9%
3.3%UK£5.04UK£4.64n/a7
Nov ’23UK£4.96
UK£4.81
-2.9%
5.4%UK£5.04UK£4.30n/a7

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$403.49

7D

0.4%

1Y

-15.5%

Patterson Companies

US$1.9b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

0KGB

US$21.68

7D

7.0%

1Y

-14.5%

Kooth

UK£66.0m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.81

7D

11.0%

1Y

-38.2%